Rehabilitation Needs for Patients Undergoing CAR T-Cell Therapy

PURPOSE OF REVIEW: Chimeric antigen receptor (CAR) T-cell therapy is a relatively new, innovative treatment strategy to manage refractory hematological cancers, including some types of leukemia, lymphoma, and multiple myeloma. This article outlines the CAR T-cell therapy process, toxicity, and compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Obaisi, Obada, Fontillas, Rhodora C., Patel, Krina, Ngo-Huang, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Cancer Rehabilitation (S Shahpar, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907385/
https://www.ncbi.nlm.nih.gov/pubmed/35267151
http://dx.doi.org/10.1007/s11912-022-01240-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907385/
https://www.ncbi.nlm.nih.gov/pubmed/35267151
http://dx.doi.org/10.1007/s11912-022-01240-0

Ejemplares similares